ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO257

Non-Proteinuric CKD: An Atypical Presentation of Multiple Myeloma

Session Information

Category: Onconephrology

  • 1700 Onconephrology


  • Pawly, Chrystel, Yale University Department of Internal Medicine, New Haven, Connecticut, United States
  • Donati, Andrew, CT Kidney and HTN Specialists LLC, Waterbury, Connecticut, United States

Light chain deposition disease (LCDD) is characterized by overproduction and deposition of monoclonal light chain immunoglobulins. LCDD usually has prominent kidney involvement; including proteinuria and kidney failure characterized by nodular glomerulosclerosis and tubular basement membrane thickening. Here we highlight an atypical presentation of biopsy proven kappa type LCDD without significant glomerular proteinuria in a patient found to have Kappa restricted Multiple myeloma (MM).

Case Description

Our patient is a 64-year-old male with medical history of asthma, hyperlipidemia, and tobacco use disorder (remission for 9 yr). He presented to nephrology clinic for evaluation of confirmed isolated elevation in creatinine of 2.1 (BUN 21) with normal CBC, electrolytes, total protein and albumin. History was negative for NSAID use, OTC supplements, frequent UTI or nephrolithiasis. There was no family history of CKD or ESKD. His only medication was Fluticasone-Vilanterol. His vital signs and physical exam were unremarkable. Urinalysis was negative for protein, but trace blood was noted. ANA, ANCA, C3/C4, RF, and viral hepatitis serologies were negative. UACR 10mcg/mg and UPCR
0.2mg/mg. SPEP was normal. Kappa FLC 273 mg/L, Lambda FLC 26.1 mg/L, Ratio 10.46. Renal imaging was notable for multiple bilateral cysts without evidence of enhancing lesion, stones or hydronephrosis. Renal biopsy was ultimately performed, and it revealed LCDD Kappa type, interstitial fibrosis/tubular atrophy of 70-80% with moderate arterio- and arteriolosclerosis. Bone marrow biopsy revealed normal cellular marrow with trilineage hematopoiesis and increased plasma cell (20% by CD 138 immunostaining). Flow cytometry revealed monoclonal kappa restricted plasma cell population. PET/CT was normal, implying that the kidneys were the sole site of the disease. He was started on cyclophosphamide, bortezomib and dexamethasone (CyBorD) and creatinine eventually improved. UACR increased slightly to 25mcg/mg.


Kidney biopsy is almost always essential when the origin of CKD is unknown. Among patients newly diagnosed with MM, 20-50% have either AKI or CKD at the time of diagnosis. Early recognition and treatment of an underlying plasma cell disorder is important in preserving kidney function. This case highlights the importance of thorough workup for monoclonal gammopathy despite absence of typical presenting features.